ReviewBiological trace element research2026
Risk of Zinc Deficiency from Urinary Zinc Loss Induced by Antihypertensive Drugs: A Narrative Review.
Review in Biological trace element research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Risk of Zinc Deficiency from Urinary Zinc Loss Induced by Antihypertensive Drugs: A Narrative Review.Biological trace element research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antihypertensive medications exhibit heterogeneous effects on zinc homeostasis, with potential clinical implications for patients at risk of zinc deficiency (ZnD). This review summarizes the effects of antihypertensive medications on zinc homeostasis, including urinary zinc (UZn) excretion, serum (SZn) and red blood cells (RBCs) zinc concentrations and the potential risk of ZnD. Angiotensin converting enzymes inhibitors (ACEIs), particularly captopril (CPT), reduce SZn by 5-13% and increase urinary zinc excretion 1.4- to 3.8-fold, with combinations with diuretics amplifying renal zinc loss up to 10.6-fold. Diuretics alone increase UZn loss by 1.6- to 3.7-fold, with minor or variable effects on SZn. Calcium channel blockers (CCBs), including verapamil and amlodipine, cause modest reductions in SZn (4.5-25.5%) and elevate RBCs zinc by 6%, whereas β-blockers (BBSs, i.e., atenolol, metoprolol) and angiotensin receptor blockers (ARBs, losartan, valsartan) resulted in decreased SZn (3.5-11%) and different effects on RBCs zinc (- 3.3% to + 3.8%). Overall, ACEIs and diuretics have the most significant impact on zinc metabolism, primarily through enhanced renal excretion, while other medications had mild effects. The important clinical take-home message of this review is that long-term use of ACEIs and diuretics may increase the risk of ZnD, particularly in older adults, patients with diabetes (who already exhibit increased UZn losses and impaired zinc metabolism), or those with low dietary zinc intake. Clinicians are therefore advised to consider zinc status and provide supplementation when deficiency is suspected.
Indexed as
Identifiers
42334829What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.